Efficacy of Photobiomodulation in the Rehabilitation of Olfactory Dysfunctions Induced by Long COVID-19

COVID-19 Clinical Trial

Official title:

Efficacy of Photobiomodulation in the Rehabilitation of Olfactory Dysfunctions Induced by Long COVID-19

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06423495
• Other study ID #: GaffreeGuinleUH
• Status: Recruiting
• Phase: N/A
• Start date: June 5, 2022
• Est. completion date: December 22, 2024

Study information

• Verified date: May 2024
• Source: Gaffree & Guinle Universitary Hospital
• Contact: DEBORAH S SALES, phd
• Phone: +5521982161520
• Email: deborahsales.fono[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

On January 30, 2020, the WHO (World Health Organization) declared the new coronavirus pandemic as the sixth public health emergency of international concern. In February 2020, the virus was designated by the Coronavirus Study Group of the International Committee on Virus Taxonomy as severe acute respiratory syndrome coronavirus 2. Many reports have described the appearance of olfactory or gustatory dysfunction simultaneously with other pre-established symptoms of COVID-19. Symptoms such as loss of taste or smell may appear 2 to 14 days after being infected with COVID-19. Worldwide, evidence regarding anosmia (loss of smell) and dysgeusia (change in taste) has been associated with COVID-19 infection. OBJECTIVES: To evaluate the effectiveness of low-intensity laser in treating changes in smell and taste after COVID-19 infection and map which changes obtained the best results. MATERIAL AND METHODS: This is an intervention study whose sample will consist of 30 individuals with loss of smell and taste for more than 6 months after COVID-19 infection, aged 18 years or older.

Description:

objective: To evaluate the effectiveness of low-intensity laser in resolving chemosensory symptoms caused by COVID-19. This is an intervention study. The sample will consist of 30 individuals who will be allocated to the low-intensity laser treatment group. The patients will come from research at the COVID-19 outpatient clinic at the Gafree Guinle University Hospital - UNIRIO. Patients who agree to participate in the study will be informed about the objective of the research and will sign an informed consent form.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: December 22, 2024
• Est. primary completion date: December 22, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Patients who complained of loss of smell and taste more than 6 months after COVID-19 infection, aged 18 years or older, with proof of infection by PCR, will be included in the study.

Exclusion Criteria:

• Patients with comorbidities prior to COVID-19 infection that could interfere with the functions of smell and taste will be excluded from the study; patients with a history of head and neck cancer, epileptic patients; mouth breathing patients; and pregnant women.

Related Conditions & MeSH terms

• Ageusia
• Anosmia
• COVID-19
• Laser Therapy
• Rehabilitation

Intervention

Device:
• low-intensity laser treatment
The experimental group will be subjected to a total of up to 24 sessions (2x a week for up to 12 weeks) of irradiation with red and infrared laser pulsed radiation, with 820mm wavelength, 60w power and 6 energy cages, applied in both nostrils and in 10 points under the tongue.

Locations

Country	Name	City	State
Brazil	university hospital Gafree Guinle	Rio de Janeiro

Sponsors (2)

Lead Sponsor	Collaborator
Gaffree & Guinle Universitary Hospital	Rio de Janeiro State Research Supporting Foundation (FAPERJ)

Country where clinical trial is conducted

Brazil, 

References & Publications (2)

Hammerle MB, Sales DS, Pinheiro PG, Gouvea EG, de Almeida PIFM, de Araujo Davico C, Souza RS, Spedo CT, Nicaretta DH, Alvarenga RMP, Pires KL, Thuler LCS, Vasconcelos CCF. Cognitive Complaints Assessment and Neuropsychiatric Disorders After Mild COVID-19 Infection. Arch Clin Neuropsychol. 2023 Feb 18;38(2):196-204. doi: 10.1093/arclin/acac093. — View Citation

Vasconcelos CCF, Hammerle MB, Sales DS, Rueda Lopes FC, Pinheiro PG, Gouvea EG, Alves MCDF, Pereira TV, Schmidt SL, Alvarenga RMP, Pires KL. Post-COVID-19 olfactory dysfunction: carbamazepine as a treatment option in a series of cases. J Neurovirol. 2022 — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	effectiveness of low-intensity laser in the treatment of olfactory dysfunction in long term covid-19	evaluate the effectiveness of low-intensity laser	20 minutes session with photobiomodulation therapy twice a week, for a total of 16 sessions

External Links

•   Post-COVID-19 Olfactory and Gustatory Dysfunction: Photobiomodulation Therapy as a Treatment Option in a Series of Cases